Offman Judith, Fitzgerald Rebecca C
Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
MRC Cancer Unit, Hutchinson/MRC Research Centre, University of Cambridge, Box 197, Cambridge Biomedical Campus, Cambridge CB2 0XZ, UK.
Gastrointest Endosc Clin N Am. 2017 Jul;27(3):379-396. doi: 10.1016/j.giec.2017.02.002. Epub 2017 Apr 4.
Barrett's esophagus (BE) predisposes patients to esophageal adenocarcinoma. 3 to 6% of individuals with gastro-esophageal reflux disease are estimated to have BE but only 20 to 25% of BE patients are currently diagnosed. The current gold standard for diagnosis of BE is per-oral upper GI endoscopy. As this is not suitable for large-scale screening, a number of alternative methods are currently being investigated: transnasal and video capsule endoscopy, endomicroscopy, cell collection devices like the cytosponge and biomarkers. Some of these are promising, however, well powered studies carried out in relevant screening populations are needed.
巴雷特食管（BE）使患者易患食管腺癌。据估计，3%至6%的胃食管反流病患者患有BE，但目前仅20%至25%的BE患者得到诊断。目前诊断BE的金标准是经口上消化道内镜检查。由于这不适合大规模筛查，目前正在研究一些替代方法：经鼻和视频胶囊内镜检查、内镜显微镜检查、细胞采集装置如细胞海绵以及生物标志物。其中一些方法很有前景，然而，需要在相关筛查人群中开展有充分说服力的研究。
